Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Raised by Ashford Capital Management Inc.

Ashford Capital Management Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 612,538 shares of the specialty pharmaceutical company’s stock after purchasing an additional 48,820 shares during the quarter. Supernus Pharmaceuticals accounts for 3.4% of Ashford Capital Management Inc.’s portfolio, making the stock its 6th largest position. Ashford Capital Management Inc.’s holdings in Supernus Pharmaceuticals were worth $30,443,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Squarepoint Ops LLC grew its stake in Supernus Pharmaceuticals by 37.4% during the 4th quarter. Squarepoint Ops LLC now owns 92,447 shares of the specialty pharmaceutical company’s stock valued at $4,595,000 after purchasing an additional 25,158 shares in the last quarter. Sofinnova Investments Inc. grew its stake in Supernus Pharmaceuticals by 46.7% during the 4th quarter. Sofinnova Investments Inc. now owns 553,095 shares of the specialty pharmaceutical company’s stock valued at $27,489,000 after purchasing an additional 176,029 shares in the last quarter. Verition Fund Management LLC grew its stake in Supernus Pharmaceuticals by 169.5% during the 4th quarter. Verition Fund Management LLC now owns 12,501 shares of the specialty pharmaceutical company’s stock valued at $621,000 after purchasing an additional 7,862 shares in the last quarter. Fieldview Capital Management LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter valued at approximately $242,000. Finally, Segall Bryant & Hamill LLC grew its stake in Supernus Pharmaceuticals by 35.5% during the 4th quarter. Segall Bryant & Hamill LLC now owns 23,233 shares of the specialty pharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 6,089 shares in the last quarter.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of recent analyst reports. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ SUPN opened at $43.58 on Wednesday. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -85.45, a price-to-earnings-growth ratio of 0.94 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a 12-month low of $30.83 and a 12-month high of $59.68. The stock’s 50 day simple moving average is $48.41 and its 200 day simple moving average is $49.53.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.